Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06347133 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Study acronym: MUIR-3
StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Study completion date changed from estimate of Sep 2026 to Sep 8, 2026
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 17 entries
  2. Primary completion date changed from estimate of May 2026 to Jun 1, 2026
    • Site details revised at 3 of 235 sites
    v20
  3. Study sites: 234 to 235v19
  4. Study sites: 231 to 234v18 Show 4 more changesShow less
    • Primary completion date: Jul 2026 to May 2026
    • Study completion date: Oct 2026 to Sep 2026
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: 16 to 17
  5. Trial status: Recruiting to Active, Not Recruitingv17 Show 4 more changesShow less
    • Enrollment target: estimated 1328 to confirmed 1456
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: 14 to 16
    • Site details revised at 231 of 231 sites
Show 15 earlier versionsHide 15 earlier versions
  1. Study sites: 212 to 231v16
  2. Study sites: 103 to 212v15
  3. Study sites: 86 to 103v14
  4. Study sites: 83 to 86v13
  5. Study sites: 74 to 83v12
  6. Study sites: 65 to 74v11
  7. Study sites: 55 to 65v10
  8. Study sites: 51 to 55v9
  9. Study sites: 26 to 51v8
  10. Study sites: 20 to 26v7
  11. Study sites: 12 to 20
    • Start date changed from estimate of May 2024 to May 21, 2024
    v6
  12. Study sites: 5 to 12v5
  13. Study sites: 2 to 5v4
  14. Study sites: 1 to 2v3
  15. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Trial Details
NCT Number NCT06347133
Lead Sponsor Arrowhead Pharmaceuticals
Conditions
(from sponsor)		 Hypertriglyceridemia
Related terms Hypertriglyceridemia
Enrollment 1,456 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov